New directions in Parkinson’s research and treatment

Bibliography

• KOLLER WC: How accurately can Parkinson's disease be diagnosed? Neurology (1992) 42:6–16
   PubMed Web of Science ®Google Scholar
• YAHR MD: Parkinson's disease: the t-DOPA era ad-vances. Neurology (1993) 60:11–17.
   Google Scholar
• LIEBERMAN A: An integrated approach to patient man-agement in Parkinson's disease. Neurol. Clin. (1992) 10:553–556.
   PubMed Web of Science ®Google Scholar
• DOONEIEF G, MIRABELLO E, BELL K et al.: An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol. (1992) 49:305–307.
   PubMedGoogle Scholar
• LIEBERMAN A: Combination therapy of Parkinson's disease. Neurology (1993) 43:2725–2726.
   PubMed Web of Science ®Google Scholar
• Neurodegeneration and Neuroprotection in Parkinson's dis-ease. Olanow CW (Ed.), Academic Press, New York, USA (1996).
   Google Scholar
• EBADI M, SRINIVASAN SK, BAXI MD: Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol (1996) 48:1–19
   PubMed Web of Science ®Google Scholar
• ••Excellent review addressing the mechanisms underlyingoxidative stress in PD and providing clues to the strategy of neuroprotection.
   Google Scholar
• POEWE W, GRANATA R: Pharmacological treatment of Parkinson's disease. In: Movement Disorders. Walts, Kol-ler WC, (Eds.), McGraw-Hill (1997) 14:201–219.
   Google Scholar
• ••An overview of current therapeutic approaches to PD withpharmacodynamic insights.
   Google Scholar
• FAHN S: Controversies in the therapy of Parkinson's disease. In: Advances in Neurology. Battistin L, Scarlato G, Caraceni T et al. (Eds.), Lippincot-Raven Publishers, Phila-delphia (1996) 69:477–486.
   Google Scholar
• HELY MA, MORRIS JGL: Controversies in the treatment of Parkinson's disease. Mov. Disord. (1996) 9:308–313.
   Google Scholar
• FISCHER P-A: Treatment strategies in Parkinson's dis-ease after a quarter century experiences with t-DOPA therapy. J. Neural. Transm. (1995) 46:S381–389.
   Google Scholar
• OLANOW CW, KORDOWER JH, FREEMAN T eta].: Fetal ni-gral transplantation as a therapy for Parkinson's dis-ease. Trends Neurosci. (1996) 19:102–109.
   Google Scholar
• FREESE A, NEVE R, GELLER Al: HSV-1 vector mediated neuronal gene delivery: strategies for neuroscience and neurology. Biochem. Pharm. (1990) 40:2189–2199.
   PubMed Web of Science ®Google Scholar
• MARKHAM CH, DIAMOND SG: Evidence to support early levodopa therapy in Parkinson's disease. Neurol-ogy (1981) 31:125–131.
   PubMed Web of Science ®Google Scholar
• RAJPUT AN, ROZDILSKY B, RAJPUT A: Levodopa efficacy and pathological basis of Parkinson syndrome. Clin. Neuropharmacol. (1990) 13:553–558.
   PubMed Web of Science ®Google Scholar
• CEDAURBAUM JM, MCDOWELL FH: Sixteen-year follow-up 100 patients begun on levodopa in 1968:emerging problems. In: Advances in Neurology. Yahr MD, Bergmann KJ, (Eds.), Raven Press, New York (1986) 45:469–472.
   Google Scholar
• JENNER P, BOYCE S, MARSDEN CD: Effect of repeated t-DOPA administration on striatal dopamine receptor. In: Recent developments in Parkinson's Disease. Fahn S, Marsden CD, Jenner P et al. (Eds.), Raven Press, New York (1986) 168:291–298.
   Google Scholar
• FAHN S: Adverse effects of levodopa. In: The Scientific Basis for the Treatment of Parkinson's Disease. Olanow CW, Lieberman AN, (Eds.), Parthenon Publishing Group, Cam-forth, UK (1992):89–111
   Google Scholar
• NAOI M, MARUYAMA W, DOSTERT P: Dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines; oxi-dation and neurotoxicity. Prog. Brain Res. (1995) 106:227–239.
   PubMed Web of Science ®Google Scholar
• RINNE UK: Controlled-release levodopa superior to standard levodopa in the treatment of early Parkin-son's disease. Mov. Disord. (1990) 5(S1):52
   Google Scholar
• PICCOLI F, RIUGGERI RM: Dopaminergic agonist in the treatment of Parkinson's disease: a review. Neural. Transm. (1995) 45:187–195
   Google Scholar
• JENNER P: The rationale for the use of dopamine ago-fists in Parkinson's disease. Neurology (1995) 45:S6–S12.
   Web of Science ®Google Scholar
• MUGUET D, BROUSOLLE E, CHAZOT G: Apomorphine in patients with Parkinson's disease. Biomed. Pharma-cother. (1995) 49:197–209.
   PubMed Web of Science ®Google Scholar
• MONTASTRUC JL, RASCOL 0, SENARD JM: Current status of dopamine agonist in Parkinson's disease manage-ment. Drugs (1993) 46(3):384–393
   PubMed Web of Science ®Google Scholar
• SCHWARTZ J-C, GIROS N. MATRES MP et al.: The dopa-mine receptor family: molecular biology and pharma-cology. Semin. Neurosci. (1992) 4:99–108.
   Google Scholar
• BARONE P, DAVIS TA, BRAUN AR et al.: Dopaminergic mechanism an d motor function: characterization of Di end D2 dopamine receptor interaction. Eur. J. Phar-macol. (1986) 123:109–114.
   PubMed Web of Science ®Google Scholar
• SIBLEY DR, MONSMA FJ, JR.: Molecular biology of dopa-mine receptor trends. Pharmacol. Sci. (1992) 13:61–69
   PubMed Web of Science ®Google Scholar
• SOKOLOFF P, MARTRES M-P, GIROS B et al.: The third do-pamine receptor (D3) as a novel target for antipsychot-ics. Biochem. Pharmacol (1992) 43:659–666.
   PubMed Web of Science ®Google Scholar
• HAVERSTIK D, RUBESTEIN A, BANNON M: Striataltachykinin gene expression regulated by interaction of Di and D2 dopamine receptors. J. Pharmacol Exp. Ther. (1989) 248:858–862.
   PubMed Web of Science ®Google Scholar
• MISSALE C, NASH SR, ROBINSON SW, JABER M, CARON MG: Dopamine receptors: from structure to function. Physiol. Rev. (1998) 78:189–225.
   PubMed Web of Science ®Google Scholar
• ••An up-to-date review on D receptors reporting a compari-son of structural and pharmacological properties.
   Google Scholar
• PATEL S, MARWOOD R, EMMS F et al.: Identification and pharmacological characterization of [12511L-750,667, a novel radioligand for the dopamine Dzi receptor. Mol. Pharmacol. (1996) 50:1658–1664
   PubMed Web of Science ®Google Scholar
• NISOLI E, TONELLO C, MEMO M, CARRUBA MO: Bio-chemical and functional identification of a novel do-pamine receptor subtype in rat brown adipose tissue. Its role in modulating sympathetic stimulation-induced thermogenesis. J. Pharmacol. Exp. Ther. (1992) 263:823–829.
   PubMed Web of Science ®Google Scholar
• TULLOCH IF: Pharmacologic profile of ropinirole: anonergoline dopamine agonist. Neurology (1997) 49(1):S58–S62.
   Web of Science ®Google Scholar
• TARAZI Fl, CAMPBELL A, YEGHIAYAN SK, BALDESSARINI RJ: Localization of dopamine receptor subtypes in cor-pus striatum and nucleus accumbens septi of rat brain: comparison of Di-, D2-, and D4-like receptors. Neurosci-ence (1998) 83:169–176.
   PubMed Web of Science ®Google Scholar
• RABEY JM: Second generation of dopamine agonists: pros and cons. J. Neural. Transm. (1995) 45:213s–224s.
   Google Scholar
• YOUDIM MBH, FINBERG JPM, TIPTON KF: Monoamino-oxidase. In: Handbook of Experimental Pharmacology Trendelenburg U, Weiner N (Eds.), Springer, Berlin (1988) 90:119–192.
   Google Scholar
• BIRKMAYER W, KNOLL J, RIEDERER P, YOUDIM MBH: (-)Deprenyl leads to prolongation of t-DOPA efficacy in Parkinson's disease. Mod. Probl. Pharmacopsych. (1982) 19:170–172.
   Google Scholar
• KALIR A, SABBAGH A, YOUDIM MBH: Selective acety-lenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br. J. Pharmacol. (1981) 73:55–64.
   PubMed Web of Science ®Google Scholar
• SALACH JI, DETMER K, YOUDIM MBH: The reaction of bovine and rat liver monoaminoxidase with[14C]clor-gyline and [14C]deprenyl. Mol. Pharmacol. (1979) 16:234–241.
   PubMed Web of Science ®Google Scholar
• SILVERMAN RB, DING CZ: Chemical model for a mecha-nism of inactivation of monoamine oxidase by hetero-cyclic compounds. Electronic effects on acetal hydrolysis. J. Am. Chem. Soc. (1993) 115:4571–4576.
   Google Scholar
• SILVERMAN RB, ZHOU JJP, DING CZ et al.: Monoamine oxidase-catalysed oxidative decarboxylation of cis-and trans-5 -aminomethy1-3 - (4 -met hoxy phe ny0 dihydrofuran-2(31)-one. Evidence for the intermedi-acy of an a-radical. J. Am. Chem. Soc. (1995) 117:12895–12896.
   Web of Science ®Google Scholar
• ••The mechanism of action of new classes of MAO inhibitors iselucidated by use of model compounds and structure-activity correlation.
   Google Scholar
• PEARCE RKB: Dopamine Di receptors agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease. Exp. Opin. Ther. Patents (1996) 6:949–953.
   Web of Science ®Google Scholar
• DELWAIDE PJ, MARTINELLI P, SCHOENEN J: Mazindol in the treatment of Parkinson's disease. Arch. Neurol. (1983) 40:788–790.
   PubMedGoogle Scholar
• CEDARBAUM JM, SCHEILFER LS: Drugs for Parkinson's disease, spasticity and acute muscule spasms. In: Phar-macological Basis of Therapeutics (18th Edition). Godman LS, Gilmann A (Eds.), Macmillan Publishing Co., New York, USA (1990) 20:463–482
   Google Scholar
• FRIEDMAN E, WANG H-Y, BUTKERAIT P: Decreased stri-atal release of acetylcholine following withdrawal from long term treatment with haloperidol: modula-tion by cholinergic, dopamine Di, D2 mechanisms. Neuropharmacology (1990) 29:537–544.
   PubMed Web of Science ®Google Scholar
• DAMSMA G, THAM CS, ROBERTSON GS, FIBIGER HC: Do-pamine Di receptors stimulation increase striatal ace-tylcholine release in the rat. Eur. j Pharmacol. (1990) 186:335–338.
   PubMed Web of Science ®Google Scholar
• KLOCKGETHER T, TURSKI L: NMDA antagonists potenti-ate antiparkinsonian action of t-DOPA in monoamine depleted rats. Ann. Neurol. (1990) 28:539–546.
   PubMed Web of Science ®Google Scholar
• ERICKSON RH, HINER RN, FEENEY SW et al.: 1,3,8-Trisubstituted xanthines. Effects of substitution pat-tern upon adenosine receptor Al/A2 affinity. J. Med. Chem. (1991) 34:1431–1435
   Google Scholar
• JENNER P, DEXTER DT, SIAN J, SCHAPIRA AHV, MARSDEN DC: Oxidative stress as a cause of nigral cell death in Parkinson's disease. Ann. Neurol (1992) 32:S82–S87.
   PubMed Web of Science ®Google Scholar
• OLANOW CW: Oxidation reaction in Parkinson's dis-ease. Neurology (1990) 40 (3) :32–37.
   PubMed Web of Science ®Google Scholar
• FHAN S, COHEN G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neu-rol. (1992) 32:804–812.
   PubMed Web of Science ®Google Scholar
• •Paper describing the basic results supporting the oxidative stress hypothesis in PD.
   Google Scholar
• SOFIC E, RIEDERER P, HEISEN H et al.: Increase iron(III) and total iron content in post-mortem substantia nigra in parkinsonian brains. J. Neural. Transm. (1988) 74:199–205.
   PubMed Web of Science ®Google Scholar
• SOFIC E, PAULUS W, JELLINGER K et al.: Selective in-crease of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. (1991) 56:978–982.
   PubMed Web of Science ®Google Scholar
• DEXTER DT, CARTER CJ, WELS FR et al.: Basal lipid per-oxidation in substantia nigra is increased in Parkin-son's disease. J. Neurochem. (1989) 52:381–389.
   PubMed Web of Science ®Google Scholar
• DEXTER DT, JENNER P, SCHAPIRA AH, MARSDEN CD: Al-teration in levels of iron ferritin and other trace metal in neurodegenerative disease affecting the basal gan-glia. Ann. Neurol (1992) 32:S94–S100.
   Web of Science ®Google Scholar
• PERRY TL, GODIN DA, HANSEN S: Parkinson's disease: a disorder due to nigral glutathione deficiency?NeuroscL Lett. (1982) 33:305–310.
   Google Scholar
• RIEDERER P, SOFIC E, RAUSCH WD et al.: Transition met-als, ferritin, glutathione and ascorbic acid in Parkin-sonian brain. J. Neurochem (1989) 52:512–520.
   Web of Science ®Google Scholar
• COHEN G: Monoamine oxidase, hydrogen peroxide and Parkinson's disease. In: Advances in Neurology. Yahr MD, Bergmann KJ (Eds.), Raven Press, New York (1986) 45:119–125.
   Google Scholar
• ADAM JD, JR., ODUNZE IN: Oxygen free radicals andParkinson's disease. Free. Rad. Biol. Med. (1991) 10:161–169.
   PubMed Web of Science ®Google Scholar
• SLIVKA A, COHEN G: Hydroxyl radical attack on dopa-mine. J. Biol. Chem. (1985) 29:15466–15472.
   Google Scholar
• NAPOLITANO A, CRESCENZI 0, PEZZELLA A et al.: Gen-eration of the neurotoxin 6-hydroxydopamine by per-oxidase/11202. J. Med. Chem. (1995) 38:917–922.
   Google Scholar
• PEZZELLA A., D'ISCHIA M, NAPOLITANO A et al.: Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contribu-tory mechanism for neuronal degeneration in Parkin-son's disease. J. Med. Chem. (1997) 42:2011–2017.
   Google Scholar
• KASTNER A, HIRSCH EC, LEJEUNE 0 et al.: Is the vulner-ability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromela-nin content? J. Neurochem. (1992) 59:1080–1089.
   Google Scholar
• JELLINGER P, KIENZL E, RUMPELMAIR G et al.: Iron-melanin complex in substantia nigra: cause of Parkin-son's disease. J. Neurochem. (1992) 59:1168–1171
   PubMed Web of Science ®Google Scholar
• BEN-SHACHAR D, RIEDERER P, YOUDIM MBH: Iron-melanin interaction and lipid peroxidation: implica-tions for Parkinson's disease. J. Neurochem. (1991) 57:1609–1614.
   PubMed Web of Science ®Google Scholar
• D'ISCHIA M, PROTA G: Biosynthesis, structure andfunction of neuromelanin and its relation to Parkin-son's disease: a critical update. Pigment Cell Res. (1997) 10:370–376.
   PubMedGoogle Scholar
• FACTOR SA, SANCHEZ-RAMOS JR, WEINER WJ: Vitamin Etherapy in Parkinson's disease. Adv. Neurol (1990) 53:457–461.
   PubMedGoogle Scholar
• ZIV I, MELAMED E, NARDI D et al.: Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons: a possible novel patogenic mechanism in Parkinson's disease. Neurosci. Lett. (1994) 170:136–140.
   PubMed Web of Science ®Google Scholar
• FREESE A, NEVE R, GELLER Al: HSV-1 vector mediated neuronal gene delivery: strategies for neuroscience and neurology. Biochem. Pharm. (1990) 40:2189–2199.
   PubMed Web of Science ®Google Scholar
• DAVIDSON BL, ALLEN ED, KOZARSKY KF et al.: A model system for in vivo gene transfer into the central nerv-ous system using an adenoviral vector. Nature Genet. (1993) 3:219–223.
   PubMed Web of Science ®Google Scholar
• KAPLITT MG, LEONE P, SAMULSKI RJ et al.: Long term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet. (1994) 8:148–154.
   PubMed Web of Science ®Google Scholar
• KLAWANS HL: Emerging strategies in Parkinson's dis-ease. Neurology (1990) 40 (Special Issue, S3):10
   Google Scholar
• VELDMAN BA, WIJN AM, KNOERS N et al.: Genetic and en-vironmental risk factors in Parkinson's disease. Clin. Neurol Neurosurg. (1998) 100(1):15–26
   PubMed Web of Science ®Google Scholar
• GOEDERT M: Familial Parkinson's disease. The awak-ening of alpha-synuclein. Nature (1997) 388:232–233.
   PubMed Web of Science ®Google Scholar
• KITADA T, ASAKAWA S, HATTORI N, MATSUMINE H et al.: Mutations in the parkin gene cause autosomal reces-sive juvenile parkinsonism. Nature (1998) 392:605–608.
   PubMed Web of Science ®Google Scholar